Cargando…

Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma

BACKGROUND: Chondrosarcoma is a common form of malignant bone tumor with limited treatment options. Approximately half of chondrosarcomas harbor gain-of-function mutations in isocitrate dehydrogenase (IDH), and mutant IDH produces 2-hydroxyglutarate (2-HG), which is an oncometabolite that contribute...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakagawa, Makoto, Yamaguchi, Masayuki, Endo, Makoto, Machida, Yukino, Hattori, Ayuna, Tanzawa, Fumie, Tsutsumi, Shinji, Kitabayashi, Issay, Kawai, Akira, Nakatani, Fumihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048072/ https://www.ncbi.nlm.nih.gov/pubmed/35493690 http://dx.doi.org/10.1016/j.jbo.2022.100430

Ejemplares similares

Oncogenic roles of enhancer of zeste homolog 1/2 in hematological malignancies
por: Nakagawa, Makoto, et al.
Publicado: (2018)

Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors
por: Shinohara, Haruka, et al.
Publicado: (2022)

Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells
por: Li, Luyuan, et al.
Publicado: (2015)

The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis
por: Wang, Tian-Xiang, et al.
Publicado: (2019)

Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant gliomas
por: Riviere-Cazaux, Cecile, et al.
Publicado: (2023)

Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation
por: Pathmanapan, Sinthu, et al.
Publicado: (2023)

D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice
por: Akbay, Esra A., et al.
Publicado: (2014)

(R)-2-hydroxyglutarate drives immune quiescence in the tumor microenvironment of IDH-mutant gliomas
por: Richardson, Leland G., et al.
Publicado: (2019)

IDH Mutations in Chondrosarcoma: Case Closed or Not?
por: Venneker, Sanne, et al.
Publicado: (2023)

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated glioma patients
por: Choi, Changho, et al.
Publicado: (2012)

Mutant IDH and non-mutant chondrosarcomas display distinct cellular metabolomes
por: Pathmanapan, Sinthu, et al.
Publicado: (2021)

Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner
por: Viswanath, Pavithra, et al.
Publicado: (2018)

Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry
por: Longuespée, Rémi, et al.
Publicado: (2018)

Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity
por: Chittaranjan, Suganthi, et al.
Publicado: (2014)

Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas
por: Leather, Thomas, et al.
Publicado: (2017)

Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth
por: Li, Luyuan, et al.
Publicado: (2020)

The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo
por: Suijker, Johnny, et al.
Publicado: (2015)

Characterization of cancer-associated IDH2 mutations that differ in tumorigenicity, chemosensitivity and 2-hydroxyglutarate production
por: Kotredes, Kevin P., et al.
Publicado: (2019)

D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth
por: Ma, Shenghong, et al.
Publicado: (2015)

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate
por: Andronesi, Ovidiu C., et al.
Publicado: (2018)

Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas
por: Autry, Adam W., et al.
Publicado: (2022)

MPC-11 IDH1/2 MUTATIONS ARE ASSOCIATED WITH SEIZURE ONSET AND VETRY IMAGING IN PATIENTS WITH DIFFUSE GLIOMA VISUALIZING 2-HYDROXYGLUTARATE BY MASS SPECTRUM
por: Ohno, Makoto, et al.
Publicado: (2019)

Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma
por: Nakagawa, Makoto, et al.
Publicado: (2018)

IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma
por: Lugowska, Iwona, et al.
Publicado: (2018)

Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation
por: Peterse, Elisabeth F. P., et al.
Publicado: (2018)

Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma
por: Venneker, Sanne, et al.
Publicado: (2020)

IMMUNOHISTOCHEMICAL ANALYSIS BY KI67 AND IDH1 IN PATIENTS WITH CHONDROSARCOMA
por: RIBEIRO, MARCELO BARBOSA, et al.
Publicado: (2023)

Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells
por: Hujber, Zoltán, et al.
Publicado: (2017)

DDRE-27. IDH MUTATED GLIOMAS PROMOTE EPILEPTOGENESIS VIA D-2-HYDROXYGLUTARATE DEPENDENT MTOR HYPERACTIVATION
por: Mortazavi, Armin, et al.
Publicado: (2021)

Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate
por: Fiehn, Oliver, et al.
Publicado: (2016)

Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate
por: Showalter, Megan Reed, et al.
Publicado: (2017)

Low pH Facilitates Heterodimerization of Mutant Isocitrate Dehydrogenase IDH1-R132H and Promotes Production of 2-Hydroxyglutarate
por: Sesanto, Rae, et al.
Publicado: (2021)

Immunological status of peripheral blood is associated with prognosis in patients with bone and soft-tissue sarcoma
por: Kim, Youngji, et al.
Publicado: (2021)

OTME-4. IDH mutated gliomas promote epileptogenesis via D-2-hydroxyglutarate dependent mTOR hyperactivation
por: Mortazavi, Armin, et al.
Publicado: (2021)

A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model
por: Wang, Fang, et al.
Publicado: (2016)

Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status
por: Venneker, Sanne, et al.
Publicado: (2019)

Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta‐analysis
por: Vuong, Huy Gia, et al.
Publicado: (2021)

The Roles of 2-Hydroxyglutarate
por: Du, Xin, et al.
Publicado: (2021)

Clonality analysis and IDH1 and IDH2 mutation detection in both components of dedifferentiated chondrosarcoma, implicated its monoclonal origin
por: Yang, Tingting, et al.
Publicado: (2020)

The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas
por: Mu, Luyan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nkiph3up67rj7q1e4kck0au09i